Síntese e caracterização de nanopartículas de prata com atividade Anti-Trypanosoma cruzi que contém fucana A da alga Spatoglossum schröederi

• Ano de defesa: 2020
• Autor(a) principal: Souza, Adriana Oliveira de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal do Rio Grande do Norte; Brasil; UFRN; PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE
• Palavras-chave em Português: Fucanas; Doença de Chagas; Alga marrom; Atividade antiTrypanosoma cruzi
• Link de acesso: https://repositorio.ufrn.br/handle/123456789/31656

The brown seaweed Spatoglossum schröederi synthesizes three types of bioactive heterofucans, the most abundant of which is fucan A. Silver nanoparticles containing fucan A (AgFuc) were produced using an environmentally friendly method. Fucan was extracted from S. schröederi and its identity was confirmed by chemical analysis, Fourier transform infrared spectroscopy (FTIR) and agarose gel electrophoresis. The synthesis of AgFuc was analyzed by UV-vis spectroscopy at kmax = 440 nm and FTIR, which confirmed the presence of silver and fucan A in the product AgFuc. Dynamic light scattering (DLS), X-ray diffraction, scanning electron microscopy and atomic force microscopy revealed that the AgFuc particles were approximately 180.0 nm in size and spherical shape. DLS also produced that AgFuc was stable for 5 months and optical coupled plasma emission spectrometry (ICP-OES) showed that the AgFuc particles contained 5% silver. AgFuc can also be more effective in inhibiting the parasites' ability to reduce MTT than fucan A or silver, regardless of treatment time. In addition, AgFuc induced the death of ~ 60% of the parasites by necrosis and ~ 17% by apoptosis. Mitochondrial damage has been identified in parasites caused by the presence of AgFuc, leading to death from necrosis and apoptosis, which suggests that AgFuc is a promising trypanocidal agent. This is the first study to analyze silver nanoparticles containing fucana as an antiTrypanosoma cruzi agent and the data encourages future preclinical studies both in vitro and in vivo.